Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ny-eso-1 plasmid dna
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intradermal (via Particle-mediated Epidermal delivery/PMED)[3]
01
Overview
NY-ESO-1 plasmid DNA is an investigational cancer vaccine that consists of a plasmid DNA encoding an immunogenic peptide derived from the cancer-testis antigen NY-ESO-1. The vaccine is designed to stimulate the immune system to recognize and attack tumor cells expressing NY-ESO-1. It has been administered using particle-mediated epidermal delivery (PMED) technology, which delivers the DNA into skin cells at high pressure. The primary mechanism involves inducing both cellular and humoral immune responses against NY-ESO-1-expressing tumors, with potential antitumor activity demonstrated in early-phase clinical trials[2][3][6]. The main indication under investigation is for various solid tumors expressing NY‑ESO‑1.
- Other names
- ny-eso-1 plasmid dna cancer vaccineny-eso1 plasmid dna cancer vaccineny-eso 1 plasmid dna cancer vaccinepPJV7611pPJV-7611pPJV 7611
02
Targets
NY-ESO-1 (New york esophageal squamous cell carcinoma 1)
Beyond the preview
Go deeper on ny-eso-1 plasmid dna.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ny-eso-1 plasmid dna.